Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment

INTRODUCTION: The VISIONARY study demonstrated statistically significant intraocular pressure (IOP) reductions with the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% (PF tafluprost/timolol FC) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients, sub-o...

Descripción completa

Detalles Bibliográficos
Autores principales: Oddone, Francesco, Kirwan, James, Lopez-Lopez, Fernando, Zimina, Marina, Fassari, Claudia, Holló, Gábor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309126/
https://www.ncbi.nlm.nih.gov/pubmed/35524840
http://dx.doi.org/10.1007/s12325-022-02166-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309126/
https://www.ncbi.nlm.nih.gov/pubmed/35524840
http://dx.doi.org/10.1007/s12325-022-02166-6

Ejemplares similares